Trial · NCT02701634
Outcomes12
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
1 to 12 of 12
Download this page as JSON| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Best Overall Response Rate | Up to 24 weeks | ITT Analysis Set: all participants who were randomized into the study. Data was analyzed according to treatment randomized. | Percentage of participants | NUMBER |
| SECONDARY | Change From Baseline in the Skin Domain of the Lee Symptom Scale (LSS) at 24 Weeks | Baseline; Week 24 | Participants in the ITT Analysis Set with available data were analyzed. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in the Mouth Domain of the LSS at 24 Weeks | Baseline; Week 24 | Participants in the ITT Analysis Set with available data were analyzed. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in the Eyes Domain of the LSS at 24 Weeks | Baseline; Week 24 | Participants in the ITT Analysis Set with available data were analyzed. | units on a scale | MEAN |
| SECONDARY | Change From Baseline in the Total Score of the LSS at 24 Weeks | Baseline; Week 24 | Participants in the ITT Analysis Set with available data were analyzed. | score on a scale | MEAN |
| SECONDARY | Duration of Response | Up to 48 weeks | ITT Analysis Set | weeks | MEDIAN |
| SECONDARY | Percentage of Participants Who Achieve at Least 50% Reduction in Systemic Corticosteroid Dose Relative to Baseline | Baseline; Up to 48 weeks | ITT Analysis Set | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Initiate Second-Line Therapy for cGVHD | Up to 48 weeks | ITT Analysis Set | Percentage of participants | NUMBER |
| SECONDARY | Failure-Free Survival | Up to 48 weeks | Participants in the ITT Analysis Set with available data were analyzed. | Days | MEDIAN |
| SECONDARY | Percentage of Participants Who Experience Any Treatment-Emergent Adverse Events (AEs) | Up to 48 weeks plus 30 days | Safety Analysis Set: all participants who received at least 1 dose of study drug, with treatment assignments designated according to actual treatment received. | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Permanently Discontinued Any Study Drug Due to an Adverse Event | Up to 48 weeks plus 30 days | Safety Analysis Set | Percentage of participants | NUMBER |
| SECONDARY | Percentage of Participants Who Experienced Treatment-Emergent Graded Laboratory Abnormalities | Up to 48 weeks plus 30 days | Safety Analysis Set | Percentage of participants | NUMBER |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02701634/outcomes